Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2011 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01496573
First received: December 16, 2011
Last updated: December 17, 2011
Last verified: December 2011

December 16, 2011
December 17, 2011
December 2011
February 2012   (final data collection date for primary outcome measure)
CRKL expression at the protein level [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01496573 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma
CRKL Expression at the Protein Level in Rhabdomyosarcoma Tumors by Tissue Microarray (TMA)

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research trial studies biomarkers in tumor tissue samples from younger patients with rhabdomyosarcoma.

OBJECTIVES:

  • To demonstrate CRKL expression at the protein level in rhabdomyosarcoma tumors by tissue microarray (TMA).

OUTLINE: Archived tumor tissue samples are analyzed for CRKL expression.

Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Sarcoma
  • Genetic: gene expression analysis
  • Genetic: microarray analysis
  • Other: laboratory biomarker analysis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
77
Not Provided
February 2012   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Alveolar rhabdomyosarcoma and embryonal rhabdomyosarcoma specimens from the Children Oncology Group (COG) tumor microarrays (TMAs)

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01496573
CDR0000719965, COG-ARST12B4
Not Provided
Peter C. Adamson, Children's Oncology Group - Group Chair Office
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Lee J. Helman, MD National Cancer Institute (NCI)
National Cancer Institute (NCI)
December 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP